Yusuke Sato

Yusuke Sato

Auto-generated profile, based on publicly available information

Yusuke Sato

Department of Urology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in Cell Reports
Verified
Journal Article
Open access
MTMariko Tabata
Mariko Tabata
YSYusuke Sato
Yusuke Sato
YKYasunori Kogure
Yasunori Kogure
MMMarni B. McClure
Marni B. McClure
YOYuji Oshikawa-Kumade
Yuji Oshikawa-Kumade
KKKeisuke Kataoka
Keisuke Kataoka
Patients with von Hippel-Lindau disease (vHL) are at risk of developing spatially and temporally multiple clear cell renal cell carcinomas (ccRCCs), which offers a valuable opportunity to analyze inter- and intra-tumor heterogeneity of genetic and immune profiles within the same patient. Here, we perform whole-exome and RNA sequencing, digital gene expression, and immunohistochemical analyses for 81 samples from 51 ccRCCs of 10 patients with vHL. Inherited ccRCCs are clonally independent and have less genomic alterations than sporadic ccRCCs. Hierarchical clustering of transcriptome profiles shows two clusters with distinct immune signatures: immune hot and cold clusters. Interestingly, not only samples from the same tumors but also different tumors from the same patients tend to show a similar immune signature, whereas samples from different patients frequently exhibit different signatures. Our findings reveal the genetic and immune landscape of inherited ccRCCs, demonstrating the relevance of host factors in shaping anti-tumor immunity.

23 August 2020 in LUTS: Lower Urinary Tract Symptoms
Verified
Journal Article
Closed access
PDF file
DWDaiji Watanabe
Daiji Watanabe
YAYoshiyuki AKIYAMA
Yoshiyuki AKIYAMA
ANAya Niimi
Aya Niimi
ANAkira Nomiya
Akira Nomiya
YYYuta Yamada
Yuta Yamada
YHYukio Homma
Yukio Homma

19 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
XLXiangyu Li
Xiangyu Li
WKWoonghee Kim
Woonghee Kim
Muhammad ArifMuhammad Arif
Muhammad Arif
CGChunxia Gao
Chunxia Gao
AHAndreas Hober
Andreas Hober
AMAdil Mardinoglu
Adil Mardinoglu
Pyruvate kinase muscle type (PKM) is a key enzyme in glycolysis and plays an important oncological role in cancer. However, the association of PKM expression and the survival outcome of patients with different cancers is controversial. We employed systems biology methods to reveal prognostic value and potential biological functions of PKM transcripts in different human cancers. Protein products of transcripts were shown and detected by western blot and mass spectrometry analysis. We focused on different transcripts of PKM and investigated the associations between their mRNA expression and the clinical survival of the patients in 25 different cancers. We find that the transcripts encoding PKM2 and three previously unstudied transcripts, namely ENST00000389093, ENST00000568883, and ENST00000561609, exhibited opposite prognostic indications in different cancers. Moreover, we validated the prognostic effect of these transcripts in an independent kidney cancer cohort. Finally, we revealed that ENST00000389093 and ENST00000568883 possess pyruvate kinase enzymatic activity and may have functional roles in metabolism, cell invasion, and hypoxia response in cancer cells. Our study provided a potential explanation to the controversial prognostic indication of PKM, and could invoke future studies focusing on revealing the biological and oncological roles of these alternative spliced variants of PKM.

15 March 2022 in Urologia Internationalis
Verified
Journal Article
Open access
PDF file
KMKatsuhiro Makino
Katsuhiro Makino
YSYusuke Sato
Yusuke Sato
RTRyosuke Takenaka
Ryosuke Takenaka
HYHideomi Yamashita
Hideomi Yamashita
YAYoshiyuki Akiyama
Yoshiyuki Akiyama
HKHaruki Kume
Haruki Kume
Objectives: This study aimed to evaluate the cumulative incidence of overall and severe radiation cystitis following external beam radiation therapy for prostate cancer and investigate the clinical factors predictive of radiation cystitis. Methods: This retrospective study comprised 246 patients who received external beam radiation therapy for localized or locally advanced prostate cancer between 2013 and 2016 in our institution. Of these, 189 received primary radiation therapy and 57 received adjuvant/salvage radiation therapy. Radiation cystitis was recorded using the Common Terminology Criteria for Adverse Events version 5.0 definition, and severe radiation cystitis was defined as grade 3 or higher. All medical records were reviewed to calculate the cumulative incidence of radiation cystitis. Univariate and multivariate Cox regression analyses were used to evaluate its association with clinicopathologic features. Results: The median follow-up period after radiation therapy was 56 months (range 5–81). The 5-year cumulative incidence of radiation cystitis and severe radiation cystitis was 16.2% and 3.0%, respectively. Multivariate analyses identified radiation therapy in the adjuvant/salvage setting was the sole risk factor associated with the development of radiation cystitis (hazard ratio: 2.75, p = 0.02). Conclusions: Radiation therapy in the post-prostatectomy setting was associated with increased risk of radiation cystitis compared with radiotherapy as the primary treatment.

8 January 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YAYoshiyuki AKIYAMA
Yoshiyuki AKIYAMA
MZMasayoshi Zaitsu
Masayoshi Zaitsu
DWDaiji Watanabe
Daiji Watanabe
IYItsuki Yoshimura
Itsuki Yoshimura
ANAya Niimi
Aya Niimi
YHYukio Homma
Yukio Homma
Electrocautery is a promising treatment option for patients with Hunner type interstitial cystitis (HIC), but frequently requires multiple sessions due to recurrence of the lesions. In the present study, we assessed the relationship between the frequency of electrocautery of Hunner lesions and changes in maximum bladder capacity (MBC) at hydrodistension in a large cohort of 118 HIC patients. Three mixed-effect linear regression analyses were conducted for MBC against (1) the number of sessions; (2) the number of sessions and the time between each session and the first session; and (3) other relevant clinical parameters in addition to the Model (2). The mean number of sessions was 2.8 times. MBC decreased approximately 50 mL for each additional electrocautery session, but this loss was offset by 10 mL for each year the subsequent session was postponed. MBC of < 400 mL at the first session was a significant risk factor for MBC loss with further sessions. No other clinical parameters were associated with MBC over time. This study demonstrates a significant relationship between the frequency of electrocautery of Hunner lesions and MBC changes in HIC patients. Low MBC at the first session is a poor prognostic marker for MBC loss over multiple sessions.

11 October 2023 in International Journal of Urology
Verified
Journal Article
Open access
YAYoshiyuki AKIYAMA
Yoshiyuki AKIYAMA
ANAya Niimi
Aya Niimi
ANAkira Nomiya
Akira Nomiya
STSatoru Taguchi
Satoru Taguchi
YYYuta Yamada
Yuta Yamada
YHYukio Homma
Yukio Homma
Objectives: To examine real-world data regarding intravesical dimethyl sulfoxide (DMSO) therapy after official approval as a treatment for Hunner-type interstitial cystitis (HIC) in Japan.Methods: This single institution, retrospective observational study was conducted between 2021 and 2022 to evaluate the outcomes of 30 patients with refractory HIC who received intravesical DMSO therapy according to the approved standardized regimen: administration of DMSO every 2 weeks for a total of 12 weeks. Treatment outcomes were evaluated using a 7-graded global response assessment scale, O'Leary and Sant's symptom and problem indices (OSSI/OSPI), the overactive bladder symptom score (OABSS), an 11-point pain intensity numerical rating scale, quality of life (QOL) score, and frequency volume chart variables. Related complications were also documented.Results: The response rates at 2, 4, 6, 8, 10, and 12 weeks were 36.7%, 43.3%, 53.3%, 60.0%, 70.0%, and 70.0%, respectively. Compared with baseline, OSSI/OSPI, pain intensity, urinary frequency, and the QOL score improved significantly from 4 weeks of treatment. The OABSS score and functional bladder capacity also showed a tendency toward moderate improvement, but the difference was not significant. The mean duration of symptom relapse after termination of treatment was 6.4 +/- 3.9 months. No patients discontinued treatment due to adverse events, although acute bladder irritation during infusion was noted in 21 patients (70%), which disappeared within 3 days.Conclusions: This study verifies the safety, moderately durable efficacy, and tolerability of the standard intravesical treatment with DMSO for HIC in Japan.